arrow
K

Kosuke Takemura

University of London
H指数:25
被引数:3,367

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of Patients with Metastatic Non–clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
2026-01-190
OAAI
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

在接受基于免疫治疗的一线治疗后转移性肾细胞癌(mRCC)中的患者流失率:来自国际mRCC数据库联盟(IMDC)的结果

2026-01-010
PRE
Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study

原发性难治性转移性肾细胞癌(mRCC)的临床特征、决定因素及后续治疗:一项国际转移数据库联盟(IMDC)研究

2025-10-010
OAAI
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab-Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

CABOSEQ 3-卡博赞替尼与舒尼替尼在一线纳武利尤单抗-伊匹木单抗治疗后的转移性肾细胞癌中的比较:一项使用国际转移性肾细胞癌数据库联盟(IMDC)真实世界数据的靶向试验模拟研究

2025-10-010
OAAI
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis

接受一线治疗后转移性肾细胞癌的无治疗生存期:一项国际转移性肾细胞癌数据库联盟分析

2025-02-011
PRE
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
2024-07-012
OAAI
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

在联合免疫疗法时代,转移性肾细胞癌患者接受延期,前期或无细胞减灭性肾切除术的特征: 来自国际转移性肾细胞癌数据库联盟的结果

2024-06-019
PRE
Anger and disgust shape judgments of social sanctions across cultures, especially in high individual autonomy societies
2024-03-071
OAAI
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
2023-11-010
PRE
Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

一线 (1L) nivolumab + ipilimumab (NIVO + IPI) 治疗转移性肾细胞癌 (mRCC) 后卡博替尼 (CABO) 与舒尼替尼 (SUN) 的比较: 使用国际mRCC数据库联盟 (IMDC) 的真实世界数据进行目标试验仿真

2023-10-012
PRE
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
2023-04-013
PRE